PMC6806250_01
PMC6806250_02
Chest X-ray scan revealed a tumor shadow in the right hilar area, an invasive shadow in the left middle and lower lung fields, and pleural effusion on both sides.
EXCLI-18-893-g-001.jpg
PMC6806250_02_EXCLI-18-893-g-001.jpg
F1
A chest X-ray (Figure 1(Fig. 1)) revealed a tumor shadow in the right hilar area, an invasive shadow in the left middle and lower lung fields, and pleural effusion on both sides. 
Computed tomography (CT) scan before administration of osimertinib. Primary lesions in the right middle and lower lobes, multiple cystic lesions in the lung field, and mild pneumothorax were observed in the right lung (a). Pleural effusion on both sides was observed (b).
EXCLI-18-893-g-002.jpg
PMC6806250_02_EXCLI-18-893-g-002.jpg
F2
PMC6806250_03
CT images after administration of osimertinib. Cavitation and decrease in size of the primary lesion were observed after 43 (a) and 81 days (b).
EXCLI-18-893-g-003.jpg
PMC6806250_03_EXCLI-18-893-g-003.jpg
F3
Respiratory state improved, and PS improved from 3 to 1, approximately 1 week from the introduction of osimertinib; cavitation and decrease in size of the primary lesion were observed via CT after 43 (Figure 3a(Fig. 3)) and 81 days (Figure 3b(Fig. 3)), respectively.